TG Therapeutics, Inc. (TGTX) Balance Sheet

The balance sheet has expanded nearly 4.3x in just over two years, reflecting the commercial success of Briumvi and strategic financing activities. However, the simultaneous rise in total liabilities from $213M to $1.0B indicates that growth is partly funded by debt, which may signal a shift from equity to leverage. Investors should monitor whether this expansion translates into sustainable profitability or merely reflects one-time financing events.

The sharp increase in debt, likely from convertible notes, has more than doubled the debt-to-equity ratio, indicating a strategic but aggressive use of leverage to fund operations and growth. While the current ratio remains healthy at 4.27, the rising debt burden could strain cash flows if interest rates rise or if revenue growth decelerates. The company's ability to service this debt will depend on sustained Briumvi sales and disciplined cost management.

The negligible investment in property, plant, and equipment underscores an asset-light business model typical of biotech firms that outsource manufacturing. The absence of goodwill suggests no significant acquisitions, keeping the balance sheet clean from intangible asset impairment risks. However, this also implies that the company's value is tied almost entirely to its intellectual property and commercial execution, which could be volatile.

The improvement in retained earnings, despite a history of losses, indicates that recent profitability is being retained to strengthen the equity base. However, the accumulated deficit remains substantial, and the equity growth is partly driven by debt and potentially stock-based compensation. Investors should assess whether the equity quality is sustainable or if it relies on non-operating gains.

The substantial increase in cash provides a robust buffer against operational shocks and supports ongoing R&D and commercial expansion. The current ratio of 4.27 indicates ample short-term liquidity, but the company's burn rate and working capital needs should be monitored. Given the low cash position relative to revenue in earlier quarters, this improvement is a positive sign, though it may be partly funded by debt.